Literature DB >> 3484979

Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects.

J C Gill, A D Wilson, J Endres-Brooks, R R Montgomery.   

Abstract

We identified a consecutive series of 12 children with noncyanotic congenital cardiac lesions with loss of the largest plasma von Willebrand factor (vWF) multimers determined by SDS-agarose electrophoresis. Seven had previous histories of mucocutaneous hemorrhage; ten had a prolonged bleeding time. Analysis of the factor VIII molecular complex revealed that six patients had reduced vWF measured both immunologically (vW:Ag) and by ristocetin cofactor assay (vW:rist). All had normal or borderline normal factor VIII procoagulant (F VIII) concentrations. Three children had prolonged partial thromboplastin times due to concurrent factor XII deficiency; none had laboratory evidence of intravascular coagulation. Five of the children were restudied after surgical correction of their cardiac lesions. Four had normalization of vWF multimers; the fifth, whose vWF was abnormal postoperatively, had a residual pressure gradient across a previous pulmonary artery banding site. Multimeric abnormalities were not found in the parents of three patients. Thus some patients with noncyanotic congenital heart disease may have an acquired abnormality of vWF that is normalized with correction of the abnormal hemodynamic state.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484979

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Acquired von Willebrand syndrome in children with patent ductus arteriosus.

Authors:  R Rauch; U Budde; A Koch; M Girisch; M Hofbeck
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

2.  Reversal of angiodysplasia-derived anemia after transcatheter aortic valve implantation.

Authors:  Stylianos A Pyxaras; Sara Santangelo; Andrea Perkan; Giancarlo Vitrella; Serena Rakar; Erica Della Grazia; Alessandro Salvi; Gianfranco Sinagra
Journal:  J Cardiol Cases       Date:  2012-03-16

3.  Von Willebrand factor multimers during transcatheter aortic valve replacement-an additional clue for detecting post-procedural aortic regurgitation?

Authors:  Andras Peter Durko; Arie Pieter Kappetein
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 4.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

5.  Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy.

Authors:  G Castaman; F Rodeghiero; E Di Bona; M Ruggeri
Journal:  Blut       Date:  1989-04

Review 6.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

7.  Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition.

Authors:  M L Avila; K-J Lee; V Bouskill; M L Rand; P James; M Carcao
Journal:  Haemophilia       Date:  2014-12-11       Impact factor: 4.287

8.  Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland.

Authors:  Geoffrey Spencer Chilvers; Graham Porter
Journal:  BMJ Case Rep       Date:  2014-08-05

Review 9.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

10.  Collagen binding provides a sensitive screen for variant von Willebrand disease.

Authors:  Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Pamela A Christopherson; Paula M Jacobi; Raymond G Hoffmann; Robert R Montgomery; Sandra L Haberichter
Journal:  Clin Chem       Date:  2013-01-22       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.